Feng Xu has over 18 years of experience leading statistical analysis of global clinical trials of all phases in therapeutic areas, including oncology, cardiovascular, inflammation, neuroscience and psychiatry. Prior to joining Rain, Feng was the vice president and head of biostatics at Puma Biotechnology, where he was responsible for the development and oversight of the biostatistics department. Before Puma Biotechnology, he was a senior manager in biostatistics at Amgen Inc., where he provided strategic and technical guidance for multiple oncology, cardiovascular and inflammation clinical trials, including six phase III pivotal trials. At Amgen Inc., he was also the lead statistician for the US filing of EVOLOCUMAB® (Repatha). Prior to Amgen Inc., he was a biostatistician at Memorial Sloan-Kettering Cancer Center and the Social Psychiatry Research Unit at Columbia University, where he collaborated with investigators and participated in clinical trial design and analysis. Feng graduated with an MS in biostatistics from Columbia University Mailman School of Public Health, where he also conducted doctoral studies.